HOME > BUSINESS
BUSINESS
- Hyperphosphatemia Treatment JTT-751 Demonstrates Non-Inferiority in PIII Study: JT, Torii
April 25, 2012
- Senju to Launch Strategic Product Aiphagan in May, Expecting Efficacy in Maintaining Field of Vision
April 24, 2012
- Astellas Senior VP Sato Shares Plans to Market Gonax Within Current Structure, MRs Dedicated to Cancer “a Future Issue”
April 24, 2012
- Wakamoto’s New Midterm Business Plan Calls for Operating, Ordinary Profits in Fiscal Year Ending March 2013
April 24, 2012
- Daiichi Sankyo to Market Ranbaxy Products in China
April 24, 2012
- Bayer Yakuhin to Set Up Committee to Promote Proper Use of Xarelto
April 23, 2012
- TPU Withdraws NDA for Aricept Transdermal Patch: Eisai
April 23, 2012
- Terapia Ranbaxy to Launch Fixed Dose Combination of Olmesartan, Amlodipine in Romania
April 23, 2012
- Daiichi Sankyo Looking to Establish “Base Treatment” Position for Memary
April 23, 2012
- Mylan, Fuso Settle with Kureha in Kremezin Generic Patent Litigation
April 20, 2012
- Kaketsuken and Astellas Enter Sales and Marketing Agreement for Inactivated Polio Combination Vaccine
April 20, 2012
- Meiji Seika Pharma Discontinues Development of Hepatitis C Drug
April 20, 2012
- Nexium No. 1 in Call Frequency in HP Market for 2nd Month in a Row: Rep Track Survey
April 20, 2012
- Bayer Yakuhin Launches Oral Factor Xa Inhibitor Xarelto
April 19, 2012
- Ono’s MS Treatment ONO-4641 Meets Primary Endpoint in PII Study
April 19, 2012
- Novartis Files for Add’l Indication of PAH for Glivec
April 19, 2012
- Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects
April 19, 2012
- JPWA, NPhA Agree to 6-Month Limit on Price Negotiations; Wholesalers’ Resolution to Be Tested for 3rd Time
April 19, 2012
- Teva Pharma Japan Aims at Early Launch of Biosimilars Marketed Overseas in Japan: President Shimada
April 18, 2012
- Dainippon Sumitomo Pharma Files for Supplemental Approval of Surepost in Combination Therapy with Biguanides and with Thiazolidinediones
April 18, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…